PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Announces Commencement of Public Offering of Common Stock
LA JOLLA, Calif. , July 19, 2017 /PRNewswire/ --  Regulus Therapeutics Inc.  (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and
View HTML
Toggle Summary Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
LA JOLLA, Calif. , June 13, 2017 /PRNewswire/ --  Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the promotion of Dr. Mark Deeg to Chief Medical Officer. Dr.
View HTML
Toggle Summary Regulus Announces Pipeline Updates and Advancements
Phase II RG-012 HERA and Renal Biopsy studies for Alport syndrome move forwardDiscontinuing clinical development of RG-101Pre-clinical pipeline progresses
View HTML
Toggle Summary Pascale Witz Joins Regulus Board of Directors
LA JOLLA, Calif. , June 1, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Pascale Witz was elected to the Company's board of directors at its Annual Meeting
View HTML
Toggle Summary Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring
Company to Restructure Operations Accompanied by a Workforce ReductionDr. Paul Grint, President and CEO, to Resign; Jay Hagan to Succeed HimConference Call Today at 5:00 p.m. ET
View HTML
Toggle Summary Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017
Conference Call and Webcast to Follow
View HTML
Toggle Summary Regulus to Present at the 16th Annual Needham Healthcare Conference
LA JOLLA, Calif. , March 28, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul C. Grint , M.D., President and Chief Executive Officer of Regulus,
View HTML
Toggle Summary Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update
RG-012 development program to include a separate biopsy study, which may provide earlier POCAnnounces final top-line 48-week results for RG-101-02 DAA combo studyConference call today at 5:00 p.m. ET
View HTML
Toggle Summary Regulus to Release Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
Conference Call and Webcast to Follow
View HTML
Toggle Summary Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD
Published results from preclinical studies show inhibition of miR-17 increased survival and reduced disease burden in mice
View HTML